Skip to main content

Human Papilloma Virus: Vaccination

Volume 485: debated on Wednesday 17 December 2008

To ask the Secretary of State for Health to what account was taken of experience in other countries using (a) Cervarix and (b) Gardisil in the appraisals undertaken to inform the decision to select Cervarix as the national Human Papilloma Virus vaccine. (242402)

The award criteria for the evaluation of the contract to supply Human papillovirus (HPV) vaccine is set out as follows. These do not include criteria regarding experience in other countries.

Criteria

Points

Quality of protection against cervical cancers caused by HPV strains 16/18

Maximum (Max) of 5,000

Duration of protection against cervical cancers caused by HPV strains 16/18 for more than 10 years duration

Max of 3,000

Quality of protection against anogenital warts caused by HPV Strains 6/11

Max of 1,300

Duration of protection against anogenital warts caused by HPV Strains 6/11 for more than 10 years duration

Max of 500

Quality of protection against HPV strains not included in the vaccine formulation

Max of 1000

Other evidence of additional clinical benefits

Max of 500

Effective Price per dose excluding VAT

Commercially confidential

Supply of the vaccine as single pre-filled syringe pack presentation

Max of 10

Quality of labelling, leaflets and presentation

Max of 5

Shelf life

Max of 120

Flexibility in the vaccine dosage schedule

Max of 70

Offers that reduce the risk of wastage if the vaccine is subject to temperatures above 8°C (this include the provision of temperature indicators and evidence based guidance on the stability of the vaccines at higher storage temperatures and subsequent safe administration.)

Max of 200

Closeness of proposed delivery schedule to Authority requirements

Max of 200

Pallet configuration including a preference for the use of Euro pallets

Max of 5

Impact of proposed amendments to the terms and conditions

(-500). Offerors may lose up to 500 points

Quality/Robustness of manufacturing contingency arrangements

Max of 10

Quality/Robustness of the risk Management of storage and distribution

Max of 10

Information provided relating to pack sizes, Cold Chain Delivery, Batch Numbering systems and production capacity

Max of 5